Alioth Empowers Chime Innovation Alliance's European Journey, Co-Creating a New Global Biopharmaceutical Ecosystem
June 6, 2025, Basel, Switzerland –Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced the opening ceremony of the Chime Biologics European Innovation Hub and the establishment of the Chime Innovation Alliance were successfully held in Basel, Switzerland. The event attracted representatives from numerous pharmaceutical and biotechnology companies in Basel, Europe, and China, as well as partners of Chime Biologics, to jointly explore the future of the biopharmaceutical industry driven by the integration of European and Chinese innovations. As a core member of the Alliance, Qijun Jia , Founder and Chairman of Alioth, was invited to attend the event, joining industry leaders to explore new frontiers of China-Europe biomedical collaboration.
Chime Innovation Alliance: Building a One-Stop Biopharmaceutical Service Platform
The Chime Innovation Alliance unites China’s leading biotechnology service providers, committed to offering clients integrated one-stop solutions for biologics development spanning drug discovery, preclinical research, clinical trials, and commercialization—supported by a comprehensive ecosystem encompassing raw material supply and specialized services. The Alliance’s capabilities will be showcased at its Innovation Hub in Basel, leveraging the city’s reputation as Europe’s premier biotechnology hub to create a seamless, efficient global support platform for clients worldwide.
During a roundtable discussion titled "Chime Biologics Innovation Alliance: Strengthening China-Europe Cooperation in Biopharmaceutical Innovation,Development, and Production," Qijun Jia shared Alioth’s global strategy: "Rooted in ‘Quality First’, Alioth has assembled an R&D team led by top membrane material scientists, established a cutting-edge membrane R&D center in Boston, and concurrently developed an intelligent manufacturing base in Shanghai to ensure seamless integration of technology transfer and process scaling. Our vision is to establish a global R&D system for filtration membrane materials and filters, providing the industry with a robust, high-quality supply chain."
As Europe remains a crucial hub for global biomedical innovation, the launch of the Chime Innovation Alliance creates an efficient platform for Sino-European biopharmaceutical collaboration. As a core member, Alioth—leveraging its deep expertise in pharmaceutical filtration technology—will collaborate with Chime Biologics and Alliance partners to deliver integrated filtration process solutions and technical support from process development to large-scale manufacturing, empowering high-quality, efficient biologics production for clients in both China and Europe.
Alioth: Empowering Global Biopharmaceuticals Through Innovative Filtration Technologies
Alioth specializes in the development and application of filtration membrane-based solutions for pharmaceutical processes, offering a comprehensive portfolio spanning depth filtration, prefiltration, sterilizing-grade filtration, filtration hardware, and laboratory-scale filtration systems. Leveraging its end-to-end capabilities in membrane R&D and industrial-scale manufacturing, the company has successfully deployed its technologies in over 20 commercial-scale (2000L/10000L) and Phase III clinical drug manufacturing processes, with more than 100 applications across monoclonal antibodies, vaccines, recombinant proteins, blood products, cell & gene therapies (CGT), and small molecules.
As a participant in the Chime Innovation Alliance, Alioth will fully utilize its expertise in membrane technology innovation and filtration process optimization to deliver tailored solutions for clients at the European Innovation Hub, accelerating their drug development pipelines and commercial production timelines.
The establishment of the Chime Innovation Alliance marks not only a new engine for Sino-European biopharmaceutical collaboration but also a microcosm of the restructuring of the global innovation ecosystem. Alioth’s participation in the Alliance signifies a deepening of its internationalization strategy. Looking ahead, Alioth will continue to collaborate closely with Chime Biologics and Alliance partners through technology sharing and resource integration, jointly enhancing the collaborative efficiency of the global biopharmaceutical value chain and contributing to the accessibility and affordability of innovative medicines.
